Quantcast

Latest Chemokine Stories

2011-06-03 13:17:57

Immune cells secrete a signal molecule that promotes atherosclerosis In Western societies, atherosclerosis of the arteries is one of the leading causes of death. Chronic, localized inflammation of the blood vessel wall facilitates the growth of fibrous plaques, which leads to narrowing or occlusion of the vessel, and thereby promotes heart attacks and stroke. The persistence of the inflammatory reaction is due to a loss of control over the activity of the immune system. So-called dendritic...

2011-02-21 14:23:47

Reoviruses are successfully being used in clinical trials to treat patients with cancer. Not only does the virus cause cancer cells to die, it also forces them to release pro-inflammatory chemokines and cytokines, which in turn causes the patient's immune system to attack the disease. New research published by BioMed Central's open access journal Molecular Cancer shows that reovirus infected cancer cells secrete proteins which, even when isolated, result in the death of cancer cells. Normal...

2011-01-26 07:30:00

MOUNTAIN VIEW, Calif., Jan. 26, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX832, an orally-administered small molecule that is a potent and selective inhibitor of the chemoattractant receptor, ChemR23. This receptor is known to regulate inflammatory cells in disease such as psoriasis. CCX832 is the fourth and final drug candidate discovered and developed by ChemoCentryx under the Company's alliance with GlaxoSmithKline (GSK)...

2011-01-06 07:30:00

MOUNTAIN VIEW, Calif., Jan. 6, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at J.P. Morgan's 29(th) Annual Healthcare Conference on Wednesday, January 12, 2011, at 10:00 a.m. Pacific at the Westin St. Francis Hotel in San Francisco, CA. About ChemoCentryx ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered...

2010-11-18 16:44:07

New research reveals a clever strategy that enables a host organism to outsmart an invading bacterium by counteracting its efforts to suppress the innate immune response. The study, published by Cell Press in the November 24th issue of the journal Immunity, describes a mechanism by which an infected cell can quickly alert unsuspecting (and uninfected) neighboring cells that can join the fight, amplify the immune response and defeat the invader. The pathogen Shigella flexneri invades the cells...

2010-11-09 08:00:00

MOUNTAIN VIEW, Calif., Nov. 9, 2010 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive Phase I clinical results for CCX354 at the Annual American College of Rheumatology Meeting (ACR). CCX354 is an orally-active small molecule that targets the chemokine receptor CCR1, instrumental in the development and progression of rheumatoid arthritis (RA). Data from the Phase I studies showed an excellent safety profile in healthy volunteers as well as in RA patients....

2010-10-08 02:23:30

The findings may lead to new drugs for cancer, immune disorders and AIDS Researchers have determined the structure of a protein that helps guide blood-forming stem cells, or hematopoetic stem cells. The protein is also one of the main receptors used by the human immunodeficiency virus (HIV) to get inside blood cells. The findings are described in the October 7, 2010 issue of the journal Science. The structure offers a detailed view of how the cell surface receptor, called CXCR4, interacts...

2010-09-21 06:30:00

MOUNTAIN VIEW, Calif., Sept. 21 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive preclinical and Phase I study results at the European Association for the Study of Diabetes (EASD). CCX140, a novel, orally bioavailable small molecule antagonist of the chemokine receptor CCR2, improved metabolic function while significantly reducing inflammatory macrophages found in adipose tissue in an animal model, and was well tolerated in Phase I clinical trials. These...

2010-06-24 15:50:43

Ulcerative colitis (UC) is characterized by frequent diarrheal attacks and anal bleeding. Histologic characteristics of UC are the invasion of the crypt epithelium and lamina propria by peripheral blood mononuclear cells (PBMCs), disruption of the epithelial lining, and consequently mucosal ulceration and crypt abscess formation in the bowel wall. Regulation of the migration of inflammatory leukocytes into the intestinal tissues is considered to be a therapeutic option for patients with UC....

2010-06-17 05:00:00

MOUNTAIN VIEW, Calif., June 17 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA). Data demonstrating that CCX354 was safe and well tolerated with a clear...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related